A Start-up Model of the Active Pharmaceutical Ingredients Business:A Case Study
碩士 === 國立中興大學 === 高階經理人碩士在職專班 === 100 === This research is based on the analysis of S company’s medical products market strategy. After finding a resource, we studied the competitive risk and technical capacity of the company. After which, we projected the direction of investment, and came up with a...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2012
|
Online Access: | http://ndltd.ncl.edu.tw/handle/y427a9 |
id |
ndltd-TW-100NCHU5457014 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-100NCHU54570142018-04-10T17:21:58Z http://ndltd.ncl.edu.tw/handle/y427a9 A Start-up Model of the Active Pharmaceutical Ingredients Business:A Case Study 企業建立新事業-原料藥案例分析 Chun-Lin Yeh 葉俊麟 碩士 國立中興大學 高階經理人碩士在職專班 100 This research is based on the analysis of S company’s medical products market strategy. After finding a resource, we studied the competitive risk and technical capacity of the company. After which, we projected the direction of investment, and came up with a business plan. The result of the research found out that S company is originated from the traditional chemical engineening industry which with more abundant resources of researches and chemical engineering, incline to the growh of inner part, develop a product to strengthen the competitive ability itself could save the initial costs. Although it has diverse products、at the pace of the product、competitive and the setup plans hae some mistakes which accumulate the activity with high fixed costs and high risk of the finance. The research suggested that with the experienced sales channel providing four to five kinds of products selections. With the competitive products in the market, S company’s pharmaceutical section used the stage investment gradually developed the manufacturing process to save the cost. The developing priority, began with the S compamy’s pharmaceutical section with initial project and competitive strength active pharmaceutical ingredients which broke the market patent、established the self patent and expand the product lift circle. At the beginning, the project emphasis on the development, didn’t invest the fixed cost in order to reduce the risk, because of the intermiate production was execute by the S company. It need to be outsourcing execute, if the terminal must have the cGMP’s factory stardard manufacture process. Junming Hsu 徐俊明 2012 學位論文 ; thesis 37 zh-TW |
collection |
NDLTD |
language |
zh-TW |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 國立中興大學 === 高階經理人碩士在職專班 === 100 === This research is based on the analysis of S company’s medical products market strategy. After finding a resource, we studied the competitive risk and technical capacity of the company. After which, we projected the direction of investment, and came up with a business plan.
The result of the research found out that S company is originated from the traditional chemical engineening industry which with more abundant resources of researches and chemical engineering, incline to the growh of inner part, develop a product to strengthen the competitive ability itself could save the initial costs. Although it has diverse products、at the pace of the product、competitive and the setup plans hae some mistakes which accumulate the activity with high fixed costs and high risk of the finance.
The research suggested that with the experienced sales channel providing four to five kinds of products selections. With the competitive products in the market, S company’s pharmaceutical section used the stage investment gradually developed the manufacturing process to save the cost. The developing priority, began with the S compamy’s pharmaceutical section with initial project and competitive strength active pharmaceutical ingredients which broke the market patent、established the self patent and expand the product lift circle. At the beginning, the project emphasis on the development, didn’t invest the fixed cost in order to reduce the risk, because of the intermiate production was execute by the S company. It need to be outsourcing execute, if the terminal must have the cGMP’s factory stardard manufacture process.
|
author2 |
Junming Hsu |
author_facet |
Junming Hsu Chun-Lin Yeh 葉俊麟 |
author |
Chun-Lin Yeh 葉俊麟 |
spellingShingle |
Chun-Lin Yeh 葉俊麟 A Start-up Model of the Active Pharmaceutical Ingredients Business:A Case Study |
author_sort |
Chun-Lin Yeh |
title |
A Start-up Model of the Active Pharmaceutical Ingredients Business:A Case Study |
title_short |
A Start-up Model of the Active Pharmaceutical Ingredients Business:A Case Study |
title_full |
A Start-up Model of the Active Pharmaceutical Ingredients Business:A Case Study |
title_fullStr |
A Start-up Model of the Active Pharmaceutical Ingredients Business:A Case Study |
title_full_unstemmed |
A Start-up Model of the Active Pharmaceutical Ingredients Business:A Case Study |
title_sort |
start-up model of the active pharmaceutical ingredients business:a case study |
publishDate |
2012 |
url |
http://ndltd.ncl.edu.tw/handle/y427a9 |
work_keys_str_mv |
AT chunlinyeh astartupmodeloftheactivepharmaceuticalingredientsbusinessacasestudy AT yèjùnlín astartupmodeloftheactivepharmaceuticalingredientsbusinessacasestudy AT chunlinyeh qǐyèjiànlìxīnshìyèyuánliàoyàoànlìfēnxī AT yèjùnlín qǐyèjiànlìxīnshìyèyuánliàoyàoànlìfēnxī AT chunlinyeh startupmodeloftheactivepharmaceuticalingredientsbusinessacasestudy AT yèjùnlín startupmodeloftheactivepharmaceuticalingredientsbusinessacasestudy |
_version_ |
1718626616868864000 |